{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:45:06Z","timestamp":1780789506648,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00520-019-04690-8","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T09:48:44Z","timestamp":1551952124000},"page":"2341-2343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Are topical beta-blockers really effective \u201cin real life\u201d for targeted therapy-induced paronychia"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"Vincent","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Casassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"4690_CR1","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","volume":"16","author":"C Robert","year":"2015","unstructured":"Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E et al (2015) Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 16:e181\u2013e189","journal-title":"Lancet Oncol"},{"key":"4690_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19:31\u201339","journal-title":"Am J Clin Dermatol"},{"key":"4690_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2340\/00015555-1097","volume":"91","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Mourey L, Chevreau C (2011) Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 91:584\u2013585","journal-title":"Acta Derm Venereol"},{"key":"4690_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","volume":"67","author":"BC Garden","year":"2012","unstructured":"Garden BC, Wu S, Lacouture ME (2012) The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 67:400\u2013408","journal-title":"J Am Acad Dermatol"},{"key":"4690_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G et al (2015) A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 372:735\u2013746","journal-title":"N Engl J Med"},{"key":"4690_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/modpathol.2012.108","volume":"25","author":"KM Chisholm","year":"2012","unstructured":"Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE (2012) \u03b2-Adrenergic receptor expression in vascular tumors. Mod Pathol 25:1446\u20131451","journal-title":"Mod Pathol"},{"key":"4690_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/pde.13372","volume":"35","author":"I Neri","year":"2018","unstructured":"Neri I, Baraldi C, Balestri R, Piraccini BM, Patrizi A (2018) Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: an open-label study in 22 children. Pediatr Dermatol 35:117\u2013120","journal-title":"Pediatr Dermatol"},{"key":"4690_CR8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/bjd.13116","volume":"171","author":"M Malik","year":"2014","unstructured":"Malik M, Murphy R (2014) A pyogenic granuloma treated with topical timolol. Br J Dermatol 171:1537\u20131538","journal-title":"Br J Dermatol"},{"key":"4690_CR9","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.jaad.2016.03.036","volume":"75","author":"N Kn\u00f6pfel","year":"2016","unstructured":"Kn\u00f6pfel N, Escudero-G\u00f3ngora MDM, Bauz\u00e0 A, Mart\u00edn-Santiago A (2016) Timolol for the treatment of pyogenic granuloma (PG) in children. J Am Acad Dermatol 75:e105\u2013e106","journal-title":"J Am Acad Dermatol"},{"key":"4690_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/pde.12217","volume":"31","author":"L Wine Lee","year":"2014","unstructured":"Wine Lee L, Goff KL, Lam JM, Low DW, Yan AC, Castelo-Soccio L (2014) Treatment of pediatric pyogenic granulomas using \u03b2-adrenergic receptor antagonists. Pediatr Dermatol 31:203\u2013207","journal-title":"Pediatr Dermatol"},{"key":"4690_CR11","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jaad.2017.12.065","volume":"78","author":"YS Baek","year":"2018","unstructured":"Baek YS, Kwon SH, Jeon J (2018) Combination of ligation and timolol before surgical excision of pyogenic granuloma. J Am Acad Dermatol 78:e141\u2013e142","journal-title":"J Am Acad Dermatol"},{"key":"4690_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/ijd.13237","volume":"55","author":"D Gupta","year":"2016","unstructured":"Gupta D, Singh N, Thappa DM (2016) Is timolol an effective treatment for pyogenic granuloma? Int J Dermatol 55:592\u2013595","journal-title":"Int J Dermatol"},{"key":"4690_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/jdv.13071","volume":"30","author":"BM Piraccini","year":"2016","unstructured":"Piraccini BM, Alessandrini A, Dika E, Starace M, Patrizi A, Neri I (2016) Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. J Eur Acad Dermatol Venereol 30:901\u2013902","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4690_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/jamadermatol.2017.4120","volume":"154","author":"X Cubir\u00f3","year":"2018","unstructured":"Cubir\u00f3 X, Planas-Ciudad S, Garcia-Muret MP, Puig L (2018) Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol 154:99\u2013100","journal-title":"JAMA Dermatol"},{"key":"4690_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"4690_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 72:203\u2013218","journal-title":"J Am Acad Dermatol"},{"key":"4690_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/CMAR.S139301","volume":"9","author":"K Capriotti","year":"2017","unstructured":"Capriotti K, Capriotti J, Pelletier J, Stewart K (2017) Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. Cancer Manag Res 9:225\u2013228","journal-title":"Cancer Manag Res"},{"key":"4690_CR18","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.jaad.2017.09.050","volume":"78","author":"CF Yen","year":"2018","unstructured":"Yen CF, Lee YY (2018) Nail braces for severe paronychia induced by epidermal growth factor receptor inhibitors: an alternative to nail extraction. J Am Acad Dermatol 78:e89\u2013e90","journal-title":"J Am Acad Dermatol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04690-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:16:36Z","timestamp":1583453796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04690-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["4690"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04690-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Sibaud reports grants from Roche, grants from Novartis, grants from BMS, grants from Bayer, grants from Pierre Fabre, and outside the submitted work. Dr. Casassa has nothing to disclose. Mirella D\u2019Andrea has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}